首页> 美国卫生研究院文献>other >Surveillance and Correlation of Antimicrobial Usage and Resistance of Pseudomonas aeruginosa: A Hospital Population-Based Study
【2h】

Surveillance and Correlation of Antimicrobial Usage and Resistance of Pseudomonas aeruginosa: A Hospital Population-Based Study

机译:铜绿假单胞菌抗菌药物使用和耐药性的监测和相关性:基于医院人群的研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This retrospective study evaluated trends and association between resistance of Pseudomonas aeruginosa isolated from patients with hospital-acquired infections (HAIs) and hospital antimicrobial usage from 2003 through 2011 in a tertiary care hospital in northeast China. HAI was defined as occurrence of infection after hospital admission, without evidence that infection was present or incubating (≦48 h) on admission. In vitro susceptibilities were determined by disk diffusion test and susceptibility profiles were determined using zone diameter interpretive criteria, as recommended by Clinical and Laboratory Standards Institute (CLSI). Data on usage of various antimicrobial agents, expressed as defined daily dose (DDD) per 1,000 patients-days developed by WHO Anatomical Therapeutical Chemical (ATC)/DDD index 2011, were collected from hospital pharmacy computer database. Most of 747 strains of P. aeruginosa were collected from respiratory samples (201 isolates, 26.9%), blood (179, 24.0%), secretions and pus (145, 19.4%) over the years. Time series analysis demonstrated a significant increase in resistance rates of P. aeruginosa to ticarcillin/clavulanic acid, piperacillin/tazobactam, cefoperazone/sulbactam, piperacillin, imipenem, meropenem, ceftazidime, cefepime, ciprofloxacin, and levofloxacin except aminoglycosides over time in the hospital (P<0.001). The rates of carbapenem-resistant P. aeruginosa (CRPA) isolated from patients with HAIs were 14.3%, 17.1%, 21.1%, 24.6%, 37.0%, 48.8%, 56.4%, 51.2%, and 54.1% over time. A significant increase in usage of anti-pseudomonal carbapenems (P<0.001) was seen. ARIMA models demonstrated that anti-pseudomonal carbapenems usage was strongly correlated with the prevalence of imipenem and meropenem-resistant P. aeruginosa (P<0.001). Increasing of quarterly CRPA was strongly correlated at one time lag with quarterly use of anti-pseudomonal carbapenems (P<0.001). Our data demonstrated positive correlation between anti-pseudomonal antimicrobial usage and P. aeruginosa resistance to several classes of antibiotics, but not all antimicrobial agents in the hospital.
机译:这项回顾性研究评估了2003年至2011年间在中国东北三级医院从医院获得性感染(HAIs)患者中分离出的铜绿假单胞菌耐药性与医院抗菌药物使用之间的趋势及其相关性。 HAI被定义为入院后发生感染,没有证据表明入院时存在感染或孵化(≤48小时)。根据临床和实验室标准协会(CLSI)的建议,通过纸片扩散测试确定体外药敏性,并使用区域直径解释性标准确定药敏谱。从医院药房计算机数据库收集有关各种抗菌剂使用情况的数据,以WHO解剖治疗化学(ATC)/ DDD指数2011年制定的每1000名患者-天的定义日剂量(DDD)表示。多年来,从呼吸道样本(201株,26.9%),血液(179例,24.0%),分泌物和脓液(145例,19.4%)中收集了大多数747株铜绿假单胞菌。时间序列分析表明铜绿假单胞菌对替卡西林/克拉维酸,哌拉西林/他唑巴坦,头孢哌酮/舒巴坦,哌拉西林,亚胺培南,美罗培南,头孢他啶,头孢吡肟,环丙沙星和左氧氟沙星的抗药率显着增加P <0.001)。从HAIs患者中分离出的耐碳青霉烯铜绿假单胞菌(CRPA)的发生率分别为14.3%,17.1%,21.1%,24.6%,37.0%,48.8%,56.4%,51.2%和54.1%。观察到抗假单胞碳青霉烯类的使用量显着增加(P <0.001)。 ARIMA模型表明,抗假单胞菌碳青霉烯类药物的使用与亚胺培南和耐美罗培南的铜绿假单胞菌的患病率密切相关(P <0.001)。季度CRPA的增加在一次滞后时间与季度使用抗假单胞菌碳青霉烯类药物密切相关(P <0.001)。我们的数据表明,抗假单胞菌的抗菌药物使用与铜绿假单胞菌对几种抗生素的耐药性呈正相关,但并非医院中的所有抗菌药物均如此。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号